Compare SIBN & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIBN | BTX |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 886.9M | 792.5M |
| IPO Year | 2018 | N/A |
| Metric | SIBN | BTX |
|---|---|---|
| Price | $15.48 | $6.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 415.2K | ★ 858.7K |
| Earning Date | 04-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.62% |
| EPS Growth | ★ 33.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,301,000.00 | N/A |
| Revenue This Year | $21.95 | N/A |
| Revenue Next Year | $15.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.53 | N/A |
| 52 Week Low | $12.50 | $5.10 |
| 52 Week High | $21.89 | $7.80 |
| Indicator | SIBN | BTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.57 | 49.86 |
| Support Level | $15.11 | $6.40 |
| Resistance Level | $15.92 | $6.74 |
| Average True Range (ATR) | 0.55 | 0.16 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 39.10 | 70.69 |
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.